News stories about ImmunoGen (NASDAQ:IMGN) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ImmunoGen earned a news impact score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.8114403507807 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
A number of brokerages recently issued reports on IMGN. Cowen and Company reiterated a “hold” rating on shares of ImmunoGen in a report on Tuesday, August 29th. BidaskClub cut ImmunoGen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Cantor Fitzgerald set a $5.00 price objective on ImmunoGen and gave the company a “hold” rating in a research note on Friday, July 28th. Zacks Investment Research lowered ImmunoGen from a “hold” rating to a “sell” rating in a research report on Monday, July 10th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of ImmunoGen in a research report on Monday, August 7th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $8.05.
ImmunoGen (NASDAQ:IMGN) traded up 8.382% on Friday, reaching $5.625. The company’s stock had a trading volume of 2,497,298 shares. The stock has a 50-day moving average of $6.74 and a 200-day moving average of $5.80. The stock’s market cap is $503.98 million. ImmunoGen has a one year low of $1.51 and a one year high of $8.84.
ImmunoGen (NASDAQ:IMGN) last released its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The business had revenue of $39.02 million during the quarter, compared to analyst estimates of $30.59 million. The business’s revenue for the quarter was up 426.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.53) EPS. On average, analysts predict that ImmunoGen will post ($0.72) EPS for the current fiscal year.
In other ImmunoGen news, VP Craig Barrows sold 37,050 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $6.81, for a total transaction of $252,310.50. Following the completion of the sale, the vice president now directly owns 51,100 shares in the company, valued at approximately $347,991. The transaction was disclosed in a document filed with the SEC, which is available through this link. 6.51% of the stock is currently owned by insiders.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/immunogen-imgn-earns-daily-media-impact-rating-of-0-16.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.